Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Novavax stock

Learn how to easily invest in Novavax stock.

Novavax Inc (NVAX) is a leading biotechnology business based in the US. It opened the day at $101.19 after a previous close of $112.38. During the day the price has varied from a low of $101.10 to a high of $112.46. The latest price was $110.82 (25 minute delay). Novavax is listed on the NASDAQ and employs 792 staff. All prices are listed in US Dollars.

How to buy shares in Novavax

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NVAX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Novavax stock price (NASDAQ: NVAX)

Use our graph to track the performance of NVAX stocks over time.

Novavax shares at a glance

Information last updated 2022-01-14.
Previous close$112.38
Change $-1.56
Change % -1.3881%
Volume 9,842,299
Information last updated 2022-01-15.
52-week range$101.10 - $331.68
50-day moving average $169.85
200-day moving average $189.02
Wall St. target price$270.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-14.95

Buy Novavax shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
Stocks, Options, ETFs
$0 per year
Get a free stock valued up to $3500
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Novavax stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novavax price performance over time

Historical closes compared with the close of $110.82 from 2022-01-19

1 week (2022-01-12) -14.87%
1 month (2021-12-17) -49.01%
3 months (2021-10-16) N/A
6 months (2021-07-20) -46.51%
1 year (2021-01-20) -11.38%
2 years (2020-01-17) 1,830.66%
3 years (2019-01-18) 5,305.85%
5 years (2017-01-20) 8,108.89%

Novavax financials

Revenue TTM $1.2 billion
Gross profit TTM $-271,429,000
Return on assets TTM -37.1%
Return on equity TTM -280.1%
Profit margin -89.31%
Book value $6.47
Market capitalisation $8.4 billion

TTM: trailing 12 months

Novavax share dividends

We're not expecting Novavax to pay a dividend over the next 12 months.

Have Novavax's shares ever split?

Novavax's shares were split on a 1:20 basis on 9 May 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novavax shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Novavax shares which in turn could have impacted Novavax's share price.

Novavax share price volatility

Over the last 12 months, Novavax's shares have ranged in value from as little as $101.1 up to $331.68. A popular way to gauge a stock's volatility is its "beta".

NVAX.US volatility(beta: 1.16)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novavax's is 1.1566. This would suggest that Novavax's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Novavax overview

Novavax, Inc. , a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. In addition, the company develops vaccine candidates for the protection against middle east respiratory syndrome, as well as that is in preclinical work associated with severe acute respiratory syndrome; and ebola virus glycoprotein vaccine candidate, as well as COVID-19 vaccine for variant strain. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc.

Frequently asked questions

What percentage of Novavax is owned by insiders or institutions?
Currently 0.57% of Novavax shares are held by insiders and 50.236% by institutions.
How many people work for Novavax?
Latest data suggests 792 work at Novavax.
When does the fiscal year end for Novavax?
Novavax's fiscal year ends in December.
Where is Novavax based?
Novavax's address is: 21 Firstfield Road, Gaithersburg, MD, United States, 20878
What is Novavax's ISIN number?
Novavax's international securities identification number is: US6700024010
What is Novavax's CUSIP number?
Novavax's Committee on Uniform Securities Identification Procedures number is: 670002104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site